Speculation Heats Up on Amarin (AMRN) After Sales Force Hiring Delayed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall St set to open higher as chips recover, megacap earnings loom
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threatÂ
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Wall St set to open higher as chips recover, megacap earnings loom
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threatÂ
- IREN raises 2026 revenue target to $4bn after $2.8bn in contracts
- AMC Entertainment posts record quarterly revenue and EBITDA in Q2 2026
Amarin (AMRN) Vascepa Pricing Leak?
December 3, 2012 3:21 PM ESTAmarin Corp Plc (NASDAQ: AMRN) investors were buzzing earlier today after a website inadvertently posted prices for Vascepa that appeared to be relatively low compared to market expectations.
GoodRx was showing prices of $51 for 30 capsules of 1g Vascepa (see below), although... More
Amarin (AMRN) Delays Hiring Vascepa Sales Reps Until Early December
November 29, 2012 7:58 AM ESTAmarin Corporation plc (Nasdaq: AMRN) previously guided that it would make a decision to hire prospective sales representatives as part of its continued Vascepa commercialization preparations before the end of November 2012.
Amarin now expects to make this decision in the first half of... More
